- Report
- January 2026
- 199 Pages
Global
From €3458EUR$3,939USD£2,992GBP
- Report
- August 2025
- 186 Pages
Global
From €3458EUR$3,939USD£2,992GBP
- Report
- February 2026
- 282 Pages
Global
From €5136EUR$5,850USD£4,443GBP
- Report
- September 2025
- 250 Pages
Global
From €3942EUR$4,490USD£3,410GBP
- Report
- September 2025
- 250 Pages
Global
From €3942EUR$4,490USD£3,410GBP
- Report
- May 2024
- 131 Pages
Global
From €3511EUR$3,999USD£3,037GBP
- Report
- July 2021
- 50 Pages
China
From €2282EUR$2,600USD£1,975GBP
- Report
- October 2024
- 101 Pages
Global
From €3500EUR$4,271USD£3,134GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$4,271USD£3,134GBP
- Report
- February 2026
- 50 Pages
Global
From €2326EUR$2,650USD£2,013GBP
- Report
- March 2025
- 215 Pages
China
From €3511EUR$4,000USD£3,038GBP
- Report
- March 2025
- 109 Pages
China
From €1580EUR$1,800USD£1,367GBP

Nifedipine is a calcium channel blocker used to treat high blood pressure and angina. It is a commonly prescribed cardiovascular drug, and is available in both immediate-release and extended-release formulations. Nifedipine is also used to treat preterm labor, Raynaud's phenomenon, and hypertrophic cardiomyopathy. It is generally well-tolerated, but can cause side effects such as headache, dizziness, and swelling.
Nifedipine is available in both generic and brand-name formulations. Brand-name formulations include Procardia, Adalat, and Nifediac. Generic formulations are available from a variety of manufacturers.
In the Nifedipine market, some of the major players include Pfizer, Bayer, Teva Pharmaceuticals, Mylan, and Sandoz. Show Less Read more